Myelodysplastic Syndromes Clinical Trials in Tampa, Florida

13 studies are recruiting for myelodysplastic syndromes in Tampa, Florida right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

   This phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   32 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT05320198 on ClinicalTrials.gov

2. A Study of BGB-11417 in Participants With Myeloid Malignancies

   The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Tampa General Hospital, Tampa, Florida

   Locations

   47 in total

   Run by

   BeOne Medicines

   See if you can join NCT04771130 on ClinicalTrials.gov

3. A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

   The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   H. Lee Moffitt Cancer Center and Research Center, Tampa, Florida

   Locations

   53 in total

   Run by

   Takeda

   See if you can join NCT04419649 on ClinicalTrials.gov

4. A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

   The main aim of this study is to find out how well elritercept works in lowering the need for RBC transfusions. Other aims are to learn how well elritercept works in reducing the need for RBC transfusions over longer periods of time or in adults with high transfusion needs. The study will also chec…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   177 in total

   Run by

   Takeda

   See if you can join NCT06499285 on ClinicalTrials.gov

5. Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

   This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manuf…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   6 in total

   Run by

   Orca Biosystems, Inc.

   See if you can join NCT07216443 on ClinicalTrials.gov

6. A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

   This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing allogeneic hematopoietic cell transplant (alloHCT) transplantation for hematologic malignancies.

   Stage

   Phase 1

   Ages

   12 to 78

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   12 in total

   Run by

   Orca Biosystems, Inc.

   See if you can join NCT03802695 on ClinicalTrials.gov

7. Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

   The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will re…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffit Cancer Center, Tampa, Florida

   Locations

   30 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT02074839 on ClinicalTrials.gov

8. A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

   A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   104 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT04988555 on ClinicalTrials.gov

9. Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

   This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Locations

   7 in total

   Run by

   Syntrix Biosystems, Inc.

   See if you can join NCT04245397 on ClinicalTrials.gov

10. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Tampa, Florida

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

11. A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

    Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS). Phase 1, Part 1 Dose Escalation - Monotherapy will evaluate the sa…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    13 in total

    Run by

    BlossomHill Therapeutics

    See if you can join NCT06501196 on ClinicalTrials.gov

12. Study of REM-422 in Patients With AML or Higher Risk MDS

    The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moffitt Cancer Center, Tampa, Florida

    Locations

    9 in total

    Run by

    Remix Therapeutics

    See if you can join NCT06297941 on ClinicalTrials.gov

13. A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

    The purpose of this study is to test the safety and efficacy (benefits) of an investigational drug LB-100, for treatment of myelodysplastic syndromes. LB-100 has previously been administered to patients with various solid tumors. In this study, LB-100 will be administered as an intravenous infusion…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

    Run by

    Lixte Biotechnology Holdings, Inc.

    See if you can join NCT03886662 on ClinicalTrials.gov